Literature DB >> 28736073

Post-eculizumab meningococcaemia in vaccinated patients.

E Lebel1, U Trahtemberg2, C Block3, O Zelig4, H Elinav3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28736073     DOI： 10.1016/j.cmi.2017.07.011

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN： 1198-743X            Impact factor:   8.067


× No keyword cloud information.
  4 in total

Review 1.  Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies.

Authors:  Joshua S Davis; David Ferreira; Emma Paige; Craig Gedye; Michael Boyle
Journal:  Clin Microbiol Rev       Date:  2020-06-10       Impact factor: 26.132

Review 2.  Complement Blockade Is a Promising Therapeutic Approach in a Subset of Critically Ill Adult Patients with Complement-Mediated Hemolytic Uremic Syndromes.

Authors:  Renaud Prével; Yahsou Delmas; Vivien Guillotin; Didier Gruson; Etienne Rivière
Journal:  J Clin Med       Date:  2022-02-01       Impact factor: 4.241

3.  Fatal Nongroupable Neisseria meningitidis Disease in Vaccinated Patient Receiving Eculizumab.

Authors:  Deirdre Nolfi-Donegan; Monica Konar; Vianca Vianzon; Jessica MacNeil; James Cooper; Perrianne Lurie; Judi Sedivy; Xin Wang; Dan M Granoff; Lucy McNamara
Journal:  Emerg Infect Dis       Date:  2018-08       Impact factor: 6.883

4.  Neonatal Atypical Hemolytic Uremic Syndrome in the Eculizumab Era.

Authors:  Sara Madureira Gomes; Rita Pissarra Teixeira; Gustavo Rocha; Paulo Soares; Hercilia Guimaraes; Paulo Santos; Joana Jardim; João Luís Barreira; Helena Pinto
Journal:  AJP Rep       Date:  2021-06-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.